General Information of Drug-Metabolizing Enzyme (DME) (ID: DET2NXO)

DME Name Monoamine oxidase type B (MAO-B)
Synonyms Amine oxidase [flavin-containing] B; Monoamine oxidase B; MAO-B; MAOB
Gene Name MAOB
UniProt ID
AOFB_HUMAN
INTEDE ID
DME0045
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Gene ID
4129
EC Number EC: 1.4.3.4
Oxidoreductase
CH-NH2 donor oxidoreductase
Oxygen acceptor oxidoreductase
EC: 1.4.3.4
Lineage Species: Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Sequence
MSNKCDVVVVGGGISGMAAAKLLHDSGLNVVVLEARDRVGGRTYTLRNQKVKYVDLGGSY
VGPTQNRILRLAKELGLETYKVNEVERLIHHVKGKSYPFRGPFPPVWNPITYLDHNNFWR
TMDDMGREIPSDAPWKAPLAEEWDNMTMKELLDKLCWTESAKQLATLFVNLCVTAETHEV
SALWFLWYVKQCGGTTRIISTTNGGQERKFVGGSGQVSERIMDLLGDRVKLERPVIYIDQ
TRENVLVETLNHEMYEAKYVISAIPPTLGMKIHFNPPLPMMRNQMITRVPLGSVIKCIVY
YKEPFWRKKDYCGTMIIDGEEAPVAYTLDDTKPEGNYAAIMGFILAHKARKLARLTKEER
LKKLCELYAKVLGSLEALEPVHYEEKNWCEEQYSGGCYTTYFPPGILTQYGRVLRQPVDR
IYFAGTETATHWSGYMEGAVEAGERAAREILHAMGKIPEDEIWQSEPESVDVPAQPITTT
FLERHLPSVPGLLRLIGLTTIFSATALGFLAHKRGLLVRV
Function
This enzyme catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
KEGG Pathway
Alcoholism (hsa05034 )
Amphetamine addiction (hsa05031 )
Arginine and proline metabolism (hsa00330 )
Cocaine addiction (hsa05030 )
Dopaminergic synapse (hsa04728 )
Drug metabolism - cytochrome P450 (hsa00982 )
Glycine, serine and threonine metabolism (hsa00260 )
Histidine metabolism (hsa00340 )
Metabolic pathways (hsa01100 )
Phenylalanine metabolism (hsa00360 )
Serotonergic synapse (hsa04726 )
Tryptophan metabolism (hsa00380 )
Tyrosine metabolism (hsa00350 )
Reactome Pathway
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB (R-HSA-141333 )

Molecular Interaction Atlas (MIA) of This DME

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DME
1 Approved Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [77]

Molecular Expression Atlas (MEA) of This DME

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DME
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2B33.1 Bone marrow 1.00E-01 2.05E-02 1.41E-01
Alopecia ED70 Skin from scalp 9.63E-01 -2.01E-02 -1.09E-01
Alzheimer's disease 8A20 Entorhinal cortex 2.65E-02 1.12E-02 6.68E-02
Ankylosing spondylitis FA92.0 Pheripheral blood 2.19E-01 -1.73E-01 -1.49E+00
Aortic stenosis BB70 Calcified aortic valve 8.65E-01 -1.48E-01 -2.29E-01
Apnea 7A40 Hyperplastic tonsil 1.33E-01 1.21E-01 1.06E+00
Arthropathy FA00-FA5Z Peripheral blood 9.25E-01 -1.17E-02 -9.23E-02
Asthma CA23 Nasal and bronchial airway 3.03E-03 -1.08E-01 -3.61E-01
Atopic dermatitis EA80 Skin 6.80E-02 4.09E-02 3.72E-01
Autism 6A02 Whole blood 9.15E-01 -2.92E-02 -1.64E-01
Autoimmune uveitis 9A96 Peripheral monocyte 7.64E-01 3.66E-03 4.55E-02
Autosomal dominant monocytopenia 4B04 Whole blood 2.57E-01 -1.21E-01 -8.26E-01
Bacterial infection of gingival 1C1H Gingival tissue 3.63E-02 2.12E-02 1.10E-01
Batten disease 5C56.1 Whole blood 9.15E-02 1.38E-01 1.10E+00
Behcet's disease 4A62 Peripheral blood 9.94E-01 7.32E-02 3.01E-01
Bipolar disorder 6A60-6A6Z Prefrontal cortex 7.35E-01 4.88E-02 3.96E-01
Bladder cancer 2C94 Bladder tissue 3.41E-04 5.70E-01 2.97E+00
Breast cancer 2C60-2C6Z Breast tissue 2.22E-08 -1.23E-01 -5.10E-01
Cardioembolic stroke 8B11.20 Whole blood 2.46E-07 1.88E-01 1.79E+00
Cervical cancer 2C77 Cervical tissue 6.83E-01 4.06E-02 1.26E-01
Childhood onset rheumatic disease FA20.Z Peripheral blood 9.69E-01 2.96E-03 1.59E-02
Chronic hepatitis C 1E51.1 Whole blood 4.20E-01 3.90E-04 2.85E-03
Chronic obstructive pulmonary disease CA22 Lung tissue 9.66E-01 1.91E-02 1.88E-01
Chronic obstructive pulmonary disease CA22 Small airway epithelium 5.03E-01 2.95E-02 2.17E-01
Chronic rhinosinusitis CA0A Sinus mucosa tissue 8.93E-01 -2.63E-02 -2.60E-01
Colon cancer 2B90 Colon tissue 1.40E-02 -3.91E-02 -1.64E-01
Coronary artery disease BA80-BA8Z Peripheral blood 4.21E-01 -3.20E-02 -3.92E-01
Diffuse large B-cell lymphoma 2A81 Tonsil tissue 1.28E-01 -7.62E-02 -7.98E-01
Endometriosis GA10 Endometrium tissue 9.80E-02 1.29E-01 5.35E-01
Familial hypercholesterolemia 5C80.00 Peripheral blood 3.27E-01 3.10E-02 3.04E-01
Familial hypercholesterolemia 5C80.00 Whole blood 3.49E-04 -1.76E-01 -7.65E-01
Gastric cancer 2B72 Gastric tissue 9.21E-02 -3.61E-01 -2.27E+00
Glioblastopma 2A00.00 Nervous tissue 4.19E-05 -1.04E-01 -4.45E-01
Glioma 2A00.0Y-2A00.0Z Brain stem tissue 4.40E-01 7.70E-02 2.52E-01
Glioma 2A00.0Y-2A00.0Z White matter tissue 5.24E-04 -3.21E-01 -1.64E+00
Head and neck cancer 2D42 Head and neck tissue 1.90E-01 3.77E-02 2.34E-01
HIV-associated neurocognitive impairment 8A2Y-8A2Z White matter tissue 4.15E-02 -3.81E-02 -2.63E-01
Huntington's disease 8A01.10 Whole blood 3.27E-01 -6.23E-02 -5.00E-01
Idiopathic pulmonary fibrosis CB03.4 Lung tissue 8.71E-01 4.88E-03 3.27E-02
Immunodeficiency 4A00-4A20 Peripheral blood 2.62E-01 -2.22E-02 -1.79E-01
Influenza 1E30 Whole blood 2.54E-01 1.71E-01 9.92E-01
Interstitial cystitis GC00.3 Bladder tissue 8.26E-01 1.54E-02 1.92E-01
Intracranial aneurysm 8B01.0 Intracranial artery 5.59E-01 1.91E-02 1.12E-01
Irritable bowel syndrome DD91.0 Rectal colon tissue 6.99E-01 9.24E-02 2.38E-01
Ischemic stroke 8B11 Peripheral blood 8.38E-01 1.67E-02 1.42E-01
Juvenile idiopathic arthritis FA24 Peripheral blood 2.01E-03 1.17E-01 5.45E-01
Lateral sclerosis 8B60.4 Skin 6.21E-01 6.06E-02 4.17E-01
Lateral sclerosis 8B60.4 Cervical spinal cord 9.70E-01 4.71E-02 1.41E-01
Liver cancer 2C12.0 Liver tissue 4.12E-01 -9.20E-02 -4.54E-01
Liver failure DB99.7-DB99.8 Liver tissue 6.04E-02 -1.91E-01 -1.23E+00
Lung cancer 2C25 Lung tissue 6.96E-01 7.52E-03 4.61E-02
Lupus erythematosus 4A40 Whole blood 1.36E-01 -6.70E-02 -2.54E-01
Major depressive disorder 6A70-6A7Z Hippocampus 3.49E-01 -2.34E-02 -1.86E-01
Major depressive disorder 6A70-6A7Z Whole blood 6.03E-01 -1.30E-02 -5.82E-02
Melanoma 2C30 Skin 4.50E-01 3.70E-02 9.32E-02
Multiple myeloma 2A83.1 Peripheral blood 8.81E-01 -2.14E-02 -1.97E-01
Multiple myeloma 2A83.1 Bone marrow 4.60E-04 -2.11E-01 -2.19E+00
Multiple sclerosis 8A40 Plasmacytoid dendritic cells 1.48E-01 -1.86E-01 -4.63E-01
Myelodysplastic syndrome 2A36-2A3Z Bone marrow 4.13E-02 -2.59E-02 -2.24E-01
Myelofibrosis 2A20.2 Whole blood 1.46E-01 4.64E-02 4.46E-01
Myocardial infarction BA41-BA50 Peripheral blood 2.72E-01 5.92E-02 2.09E-01
Myopathy 8C70.6 Muscle tissue 7.72E-02 -2.73E-01 -6.75E-01
Neonatal sepsis KA60 Whole blood 4.12E-02 -6.28E-02 -2.99E-01
Neuroectodermal tumour 2A00.11 Brain stem tissue 2.34E-04 -4.92E-01 -1.84E+00
Non-alcoholic fatty liver disease DB92 Liver tissue 3.60E-01 -5.69E-03 -2.81E-02
Obesity related type 2 diabetes 5A11 Omental adipose tissue 1.78E-01 2.70E-02 2.38E-01
Olive pollen allergy CA08.00 Peripheral blood 9.78E-01 7.01E-02 2.70E-01
Oral cancer 2B6E Oral tissue 3.79E-06 -3.06E-01 -1.38E+00
Osteoarthritis FA00-FA0Z Synovial tissue 6.92E-01 2.52E-02 7.07E-02
Osteoporosis FB83.1 Bone marrow 7.39E-01 -2.39E-02 -1.07E-01
Ovarian cancer 2C73 Ovarian tissue 1.16E-01 -1.76E-01 -6.23E-01
Pancreatic cancer 2C10 Pancreas 4.31E-03 -2.77E-01 -7.45E-01
Parkinson's disease 8A00.0 Substantia nigra tissue 9.83E-01 3.54E-02 1.89E-01
Pediatric respiratory syncytial virus infection CA40.11 Peripheral blood 3.17E-01 -4.86E-02 -6.25E-01
Pituitary cancer 2D12 Pituitary tissue 4.64E-01 2.79E-02 1.11E-01
Pituitary gonadotrope tumour 2D12 Pituitary tissue 2.87E-01 -2.89E-02 -9.99E-02
Polycystic ovary syndrome 5A80.1 Vastus lateralis muscle 6.36E-03 -1.10E-01 -8.32E-01
Polycythemia vera 2A20.4 Whole blood 1.52E-03 7.99E-02 8.33E-01
Pompe disease 5C51.3 Biceps muscle 5.41E-01 1.81E-01 4.65E-01
Preterm birth KA21.4Z Myometrium 1.58E-01 0.00E+00 0.00E+00
Prostate cancer 2C82 Prostate 4.78E-02 -2.05E-01 -6.98E-01
Psoriasis EA90 Skin 2.58E-02 -5.36E-02 -2.77E-01
Rectal cancer 2B92 Rectal colon tissue 6.41E-01 -4.50E-02 -1.92E-01
Renal cancer 2C90-2C91 Kidney 1.90E-02 -2.32E-01 -1.00E+00
Retinoblastoma 2D02.2 Uvea 7.97E-02 -1.95E-01 -1.49E+00
Rheumatoid arthritis FA20 Synovial tissue 2.22E-01 -3.12E-02 -9.03E-02
Rhinovirus infection CA42.1 Nasal epithelium tissue 1.02E-01 4.98E-02 3.93E-01
Schizophrenia 6A20 Prefrontal cortex 3.29E-01 -3.98E-03 -1.64E-02
Schizophrenia 6A20 Superior temporal cortex 7.29E-01 2.98E-04 2.38E-03
Scleroderma 4A42.Z Whole blood 3.36E-01 -4.19E-02 -3.15E-01
Seizure 8A60-8A6Z Whole blood 6.01E-01 -6.88E-02 -3.75E-01
Sensitive skin EK0Z Skin 2.78E-01 1.67E-02 1.98E-01
Sepsis with septic shock 1G41 Whole blood 2.44E-01 4.27E-02 2.15E-01
Shwachman-Diamond syndrome 3A70.0 Bone marrow 4.66E-01 1.60E-01 6.59E-01
Sickle cell disease 3A51.0-3A51.3 Peripheral blood 7.44E-01 -7.53E-03 -3.97E-02
Simpson golabi behmel syndrome LD2C Adipose tissue 5.62E-01 3.55E-03 7.57E-02
Sjogren's syndrome 4A43.2 Salivary gland tissue 4.65E-01 2.77E-02 5.48E-01
Skin cancer 2C30-2C3Z Skin 3.54E-04 5.85E-02 2.41E-01
Thrombocythemia 3B63 Whole blood 2.50E-01 7.08E-02 6.94E-01
Thrombocytopenia 3B64 Whole blood 9.03E-01 6.88E-02 3.98E-01
Thyroid cancer 2D10 Thyroid 6.72E-05 8.87E-02 5.19E-01
Tibial muscular dystrophy 8C75 Muscle tissue 1.26E-04 -7.80E-01 -1.37E+00
Tuberous sclerosis complex LD2D.2 Perituberal tissue 2.55E-01 2.34E-01 9.97E-01
Type 2 diabetes 5A11 Liver tissue 5.08E-01 -2.92E-02 -1.76E-01
Ureter cancer 2C92 Urothelium 1.90E-01 -4.56E-02 -2.29E-01
Uterine cancer 2C78 Endometrium tissue 1.14E-05 -1.21E-01 -4.52E-01
Vitiligo ED63.0 Skin 3.59E-01 2.48E-02 8.45E-02
------------------------------------------------------------------------------------
⏷ Show the Full List of DME Expression Under 107 Diseases

The Drug Therapeutic Target (DTT) Role of This DME

DME DTT Name Monoamine oxidase type B (MAO-B) DTT Info
DME DTT Type Successful
11 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Budipine DMODHQI Migraine 8A80 Approved [1]
Indeloxazine DMWO3N6 Dementia 6D80-6D86 Approved [2]
Pargyline DMM0HR1 Hypertension BA00-BA04 Approved [3]
Phenelzine DMHIDUE Depression 6A70-6A7Z Approved [4]
Rasagiline DM3WKQ4 Parkinson disease 8A00.0 Approved [5]
Safinamide DM0YWJC Parkinson disease 8A00.0 Approved [6]
Safinamide mesylate DM0J2ZT Parkinson disease 8A00.0 Approved [7]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [8]
Selegiline Hydrochloride DM3VR1L Parkinson disease 8A00.0 Approved [9]
Sulphadoxine DMZI2UF Malaria 1F40-1F45 Approved [10]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [11]
⏷ Show the Full List of 11 Approved Drug(s)
11 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
P2B-001 DM9PVHX Parkinson disease 8A00.0 Phase 3 [12]
Psoralen DMIZJ8M N. A. N. A. Phase 3 [13]
TRYPTAMINE DMAFPHB N. A. N. A. Phase 3 [14]
CHF-3381 DMQ2O8V Neuropathic pain 8E43.0 Phase 2 [15]
EVT302 DM73XNG Alzheimer disease 8A20 Phase 2 [16]
Ladostigil DMJSY3Q Alzheimer disease 8A20 Phase 2 [17]
ORY-2001 DMYM0UY Alzheimer disease 8A20 Phase 2 [18]
RG1577 DMT1ZX0 Alzheimer disease 8A20 Phase 2 [19]
Neu-120 DMXKOUC Parkinson disease 8A00.0 Phase 1/2 [20]
PIPERINE DMYEAB1 Vitiligo ED63.0 Phase 1/2 [21]
PF9601N DMGLEM1 Parkinson disease 8A00.0 Phase 1 [22]
⏷ Show the Full List of 11 Clinical Trial Drug(s)
73 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
3,4-Dihydroxybenzaldehyde DM4O3DW N. A. N. A. Patented [23]
3-Hydroxy-2-butanone DM9GPKR N. A. N. A. Patented [23]
4-Hydroxy-2,5-dimethyl-3(2H)-furanone DM9L5KO N. A. N. A. Patented [23]
4-hydroxybenzaldehyde DM471P5 Discovery agent N.A. Patented [23]
4-Hydroxybenzoicacid DM3WQNY N. A. N. A. Patented [23]
4-Hydroxybenzylalcohol DMKDZMQ N. A. N. A. Patented [23]
4-Methoxybenzaldehyde DMN6GTZ N. A. N. A. Patented [23]
Benzylcinnamate DMD7Z3H N. A. N. A. Patented [23]
Coumaricacid DM3ZGBH N. A. N. A. Patented [23]
Coumarin/resveratrol hybrid derivative 1 DMI1BKA N. A. N. A. Patented [24]
Coumarin/resveratrol hybrid derivative 2 DMK12OT N. A. N. A. Patented [24]
Cyclic peptide derivative 1 DM78NOU N. A. N. A. Patented [25]
Ethylvanillin DM9WMJ1 N. A. N. A. Patented [23]
EUGENOL DM7US1H Discovery agent N.A. Patented [23]
FERULIC ACID DMJC7NF Discovery agent N.A. Patented [23]
Heteroaryl-cyclopropylamine derivative 1 DMRF58Q N. A. N. A. Patented [25]
Heteroaryl-cyclopropylamine derivative 3 DMH9EQ1 N. A. N. A. Patented [25]
Lazabemide DMCULK7 Skin imperfections EK71 Patented [26]
Lazabemide analog 1 DM189D7 N. A. N. A. Patented [24]
N-(2-phenylcyclopropyl) amino acid derivative 1 DMH7T8C N. A. N. A. Patented [25]
N-(2-phenylcyclopropyl) amino acid derivative 3 DMFBRSL N. A. N. A. Patented [25]
Piperonal DME26SY N. A. N. A. Patented [23]
PMID25399762-Compound-Table 6-10 DM4UM03 N. A. N. A. Patented [23]
PMID25399762-Compound-Table 6-11 DMYGTU2 N. A. N. A. Patented [23]
PMID25399762-Compound-Table 6-12 DMZ07RP N. A. N. A. Patented [23]
PMID25399762-Compound-Table 6-13 DM6LR42 N. A. N. A. Patented [23]
PMID25399762-Compound-Table 6-14 DMZHB9Y N. A. N. A. Patented [23]
PMID25399762-Compound-Table 6-15 DMCHWSF N. A. N. A. Patented [23]
PMID25399762-Compound-Table 6-9 DMDWIPG N. A. N. A. Patented [23]
PMID25399762-Compound-Table 7-Vanillic acid DMSL3MB N. A. N. A. Patented [23]
PMID25399762-Compound-Table 7-Vanillyl alcohol DM759MJ N. A. N. A. Patented [23]
PMID25399762-Compound-Table 7-Veratraldehyde DM4J2SM N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C1 DMMP7HX N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C10 DMWY5XT N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C11 DMVASXW N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C12 DMF9X6P N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C13 DMD80Q6 N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C14 DM7960M N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C15 DMR0P1U N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C16 DMYTEAC N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C17 DMNMU3R N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C18 DM2ZUVH N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C19 DMMO3F1 N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C2 DMPFLGO N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C20 DMITNWZ N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C21 DMMFILA N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C22 DMBE0R2 N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C23 DMF89PY N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C24 DMJK296 N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C25 DMHT41B N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C3 DMXAKNH N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C4 DMJCVBM N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C5 DMEJNUG N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C6 DMY3UKC N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C7 DMQJV3L N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C8 DMRCPKV N. A. N. A. Patented [23]
PMID25399762-Compound-Table1-C9 DMVMT26 N. A. N. A. Patented [23]
PMID29324067-Compound-38 DMPXZYN N. A. N. A. Patented [24]
PMID29324067-Compound-40 DM69A05 N. A. N. A. Patented [24]
PMID29757691-Compound-4 DMFD9UZ N. A. N. A. Patented [27]
Schiff base compound 1 DMQD6IL Alzheimer disease 8A20 Patented [24]
Schiff base compound 2 DMWD20L Alzheimer disease 8A20 Patented [24]
Secondary and tertiary (hetero)arylamide derivative 1 DMEDNTJ N. A. N. A. Patented [24]
T83193 DMHO29Y Discovery agent N.A. Patented [23]
Tacrine-coumarin hybrid derivative 1 DM6YBTR N. A. N. A. Patented [24]
Tarnylcypromine derivative 2 DMEJR2F N. A. N. A. Patented [25]
Tarnylcypromine derivative 3 DMKJOMC N. A. N. A. Patented [25]
Tetra-hydro-isoquinoline derivative 1 DML86IO N. A. N. A. Patented [27]
Tetra-hydro-isoquinoline derivative 2 DM5CKVF N. A. N. A. Patented [27]
Tetra-hydro-isoquinoline derivative 3 DMCZA45 N. A. N. A. Patented [27]
Tetra-hydro-isoquinoline derivative 4 DMDV0MP N. A. N. A. Patented [27]
Tetra-hydro-oxazolopyridine derivative 1 DM72MDA N. A. N. A. Patented [28]
Tetra-hydro-oxazolopyridine derivative 2 DMP65Z4 N. A. N. A. Patented [28]
⏷ Show the Full List of 73 Patented Agent(s)
6 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOFEGILINE DMJ59A4 Cognitive impairment 6D71 Discontinued in Phase 3 [29]
AS602868 DMKXDOI Multiple myeloma 2A83 Discontinued in Phase 1 [13]
EVT-301 DMCZ8SF Alzheimer disease 8A20 Discontinued in Phase 1 [30]
HT-1067 DMUPOIG Parkinson disease 8A00.0 Discontinued in Phase 1 [31]
SL-25.1188 DMP0DLW Alzheimer disease 8A20 Discontinued in Phase 1 [32]
Milacemide DMJTR0U Alzheimer disease 8A20 Terminated [33]
⏷ Show the Full List of 6 Discontinued Drug(s)
1 Preclinical Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
RWJ-416457 DMH1FRY Bacterial infection 1A00-1C4Z Preclinical [8]
237 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(+/-)-2-(4'-Benzyloxyphenyl)thiomorpholin-5-one DMDXKQ6 Discovery agent N.A. Investigative [34]
(+/-)-2-(4'-Benzyloxyphenyl)thiomorpholine DMCB74T Discovery agent N.A. Investigative [34]
(+/-)-2-(4'-Butoxyphenyl)thiomorpholin-5-one DM1WCJV Discovery agent N.A. Investigative [34]
(+/-)-2-(4'-Butoxyphenyl)thiomorpholine DMG3MF2 Discovery agent N.A. Investigative [34]
(+/-)-2-(4'-Ethoxyphenyl)thiomorpholin-5-one DM1YBJ2 Discovery agent N.A. Investigative [34]
(+/-)-2-(4'-Ethoxyphenyl)thiomorpholine DMKPX7W Discovery agent N.A. Investigative [34]
(+/-)-2-(4'-Methoxyphenyl)thiomorpholin-5-one DM7BY4T Discovery agent N.A. Investigative [34]
(+/-)-2-(4'-Methoxyphenyl)thiomorpholine DMKFSQ8 Discovery agent N.A. Investigative [34]
(+/-)-2-(4'-Propoxyphenyl)thiomorpholin-5-one DMY1W20 Discovery agent N.A. Investigative [34]
(+/-)-2-(4'-Propoxyphenyl)thiomorpholine DMUPYN1 Discovery agent N.A. Investigative [34]
(+/-)-2-(4-fluorophenyl)-7-methoxychroman-4-one DMGY5WB Discovery agent N.A. Investigative [35]
(+/-)-2-(4-fluorophenyl)-7-methylchroman-4-one DMHL7BC Discovery agent N.A. Investigative [35]
(+/-)-2-(4-fluorophenyl)chroman-4-one DMXK4HR Discovery agent N.A. Investigative [35]
(+/-)-2-(4-methoxyphenyl)-7-methylchroman-4-one DMTUFOE Discovery agent N.A. Investigative [35]
(+/-)-2-p-tolylchroman-4-one DMYJGZ4 Discovery agent N.A. Investigative [35]
(+/-)-2-Phenylthiomorpholin-5-one DMSHDNO Discovery agent N.A. Investigative [34]
(+/-)-2-Phenylthiomorpholine DMNR3YL Discovery agent N.A. Investigative [34]
(+/-)-7-fluoro-2-(4-fluorophenyl)chroman-4-one DMKWBY8 Discovery agent N.A. Investigative [35]
(+/-)-7-fluoro-2-(4-methoxyphenyl)chroman-4-one DMYHV9P Discovery agent N.A. Investigative [35]
(+/-)-7-fluoro-2-p-tolylchroman-4-one DM4H1JO Discovery agent N.A. Investigative [35]
(+/-)-7-fluoro-2-phenylchroman-4-one DMJEBXA Discovery agent N.A. Investigative [35]
(+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one DMYJGDK Discovery agent N.A. Investigative [35]
(+/-)-7-methoxy-2-p-tolylchroman-4-one DMJMTVQ Discovery agent N.A. Investigative [35]
(+/-)-7-methoxy-2-phenylchroman-4-one DMC0OKA Discovery agent N.A. Investigative [35]
(+/-)-7-methyl-2-p-tolylchroman-4-one DMBN3WE Discovery agent N.A. Investigative [35]
(+/-)-7-methyl-2-phenylchroman-4-one DMI3URD Discovery agent N.A. Investigative [35]
(6-Benzyloxy-2-naphthyl)-2-aminopropane DMF7LST Discovery agent N.A. Investigative [36]
(6-Ethoxy-2-naphthyl)-2-aminopropane DMM2EX6 Discovery agent N.A. Investigative [36]
(6-Methoxy-2-naphthyl)-2-aminopropane DM6YGQ3 Discovery agent N.A. Investigative [36]
(6-Propoxy-2-naphthyl)-2-aminopropane DMIFL3V Discovery agent N.A. Investigative [36]
(7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile DMB9YAO Discovery agent N.A. Investigative [37]
(E)-5-(3-Chlorostyryl)isatin DMLIQUA Discovery agent N.A. Investigative [38]
(E)-5-(3-Fluorostyryl)isatin DMP4T9Z Discovery agent N.A. Investigative [38]
(E)-5-Styrylisatin DM1PCIX Discovery agent N.A. Investigative [38]
(E)-6-Styrylisatin DMG47QU Discovery agent N.A. Investigative [38]
(E)-8-(3-chlorostyryl)-caffeine DMQT15Z Discovery agent N.A. Investigative [39]
(R)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one DM5UOFY Discovery agent N.A. Investigative [35]
(R)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one DM6WTLZ Discovery agent N.A. Investigative [35]
(R)(+)-7-fluoro-2-p-tolylchroman-4-one DMHNKWR Discovery agent N.A. Investigative [35]
(R)(+)-7-fluoro-2-phenylchroman-4-one DMJCN0Y Discovery agent N.A. Investigative [35]
(R)(+)-7-methyl-2-p-tolylchroman-4-one DMVN50D Discovery agent N.A. Investigative [35]
(R)(+)-7-methyl-2-phenylchroman-4-one DM8ZHYR Discovery agent N.A. Investigative [35]
(R)-3-Prop-2-ynylamino-indan-5-ol DMPEV2W Discovery agent N.A. Investigative [40]
(R)-Indan-1-yl-methyl-prop-2-ynyl-amine DMKFPMC Discovery agent N.A. Investigative [41]
(R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide DMPKWIN Discovery agent N.A. Investigative [42]
(R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide DMEVM6G Discovery agent N.A. Investigative [42]
(R)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide DMU49JN Discovery agent N.A. Investigative [42]
(R/R)BEFLOXATONE DM8I6MG Discovery agent N.A. Investigative [43]
(S)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one DMC5Z2I Discovery agent N.A. Investigative [35]
(S)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one DMILWE7 Discovery agent N.A. Investigative [35]
(S)(+)-7-fluoro-2-p-tolylchroman-4-one DMTFZBQ Discovery agent N.A. Investigative [35]
(S)(+)-7-fluoro-2-phenylchroman-4-one DMHR1IB Discovery agent N.A. Investigative [35]
(S)(+)-7-methyl-2-p-tolylchroman-4-one DMVBD6H Discovery agent N.A. Investigative [35]
(S)(+)-7-methyl-2-phenylchroman-4-one DMBG4KN Discovery agent N.A. Investigative [35]
(S)-2-amino-1-(4-butylthiophenyl)-propane DMPQ53V Discovery agent N.A. Investigative [44]
(S)-2-amino-1-(4-propylthiophenyl)-propane DMAN7YJ Discovery agent N.A. Investigative [44]
(S)-N2-[4-(benzyloxy)benzyl]alaninamide DMGMAPB Discovery agent N.A. Investigative [42]
(S)-N2-[4-(benzyloxy)benzyl]serinamide DMW5ZK7 Discovery agent N.A. Investigative [42]
(S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide DMKMJBL Discovery agent N.A. Investigative [42]
(S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide DMINLCJ Discovery agent N.A. Investigative [42]
(S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}serinamide DMSC8ZW Discovery agent N.A. Investigative [42]
(S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}alaninamide DMU3F7H Discovery agent N.A. Investigative [42]
(S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}serinamide DMLFOPV Discovery agent N.A. Investigative [42]
(S)-N2-{4-[(4-nitrobenzyl)oxy]benzyl}serinamide DMLP63J Discovery agent N.A. Investigative [42]
1,2,3,4-Tetrahydro-naphthalen-1-ylamine DMNXQ7Z Discovery agent N.A. Investigative [45]
1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole DM3JGVF Discovery agent N.A. Investigative [46]
1,4-diphenyl-(1E,3E)-1,3-butadiene DMFY3VS Discovery agent N.A. Investigative [41]
1-(4-(benzyloxy)phenyl)propan-2-amine DMT81N3 Discovery agent N.A. Investigative [36]
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine DMPWB8G Discovery agent N.A. Investigative [47]
1H-Indole-2,3-dione DMOZ91H Discovery agent N.A. Investigative [48]
2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole DMX8NYD Discovery agent N.A. Investigative [14]
2-(2,4-dichlorophenyl)-4,5-dihydro-1H-imidazole DMDUF21 Discovery agent N.A. Investigative [49]
2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole DM187UQ Discovery agent N.A. Investigative [50]
2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole DMTFWAQ Discovery agent N.A. Investigative [50]
2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole DMPNGXE Discovery agent N.A. Investigative [50]
2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole DMH1VCE Discovery agent N.A. Investigative [50]
2-(3-nitrophenyl)-4,5-dihydro-1H-imidazole DMMYQ9R Discovery agent N.A. Investigative [49]
2-(4,5-dihydro-1H-imidazol-2-yl)quinoline DM4X0SJ Discovery agent N.A. Investigative [49]
2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole DMFQI4C Discovery agent N.A. Investigative [49]
2-(4-fluorophenyl)-7-methoxy-4H-chromen-4-one DMZDGB3 Discovery agent N.A. Investigative [35]
2-(4-methoxyphenyl)-4H-chromene-4-thione DMIDXTR Discovery agent N.A. Investigative [35]
2-(5-phenyl-furan-2-yl)-4,5-dihydro-1H-imidazole DMDZ9RK Discovery agent N.A. Investigative [51]
2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole DMKY71Z Discovery agent N.A. Investigative [49]
2-BFi DMFAW4R Discovery agent N.A. Investigative [49]
2-Bromo-N-(2-morpholinoethyl)nicotinamide DMYCENM Discovery agent N.A. Investigative [52]
2-Bromo-N-(3-morpholinopropyl)nicotinamide DM9NMIO Discovery agent N.A. Investigative [52]
2-Chloro-N-(2-morpholinoethyl)nicotinamide DMR8M36 Discovery agent N.A. Investigative [52]
2-Chloro-N-(3-morpholinopropyl)nicotinamide DM5S1DW Discovery agent N.A. Investigative [52]
2-Furan-2-yl-4,5-dihydro-1H-imidazole DMQIFJ9 Discovery agent N.A. Investigative [53]
2-Hydrazino-3-methyl-4(3H)-quinazolinone DMOT1LQ Discovery agent N.A. Investigative [54]
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one DMEVFJW Discovery agent N.A. Investigative [55]
2-oxo-N-m-tolyl-2H-chromene-3-carboxamide DMDKSZ0 Discovery agent N.A. Investigative [56]
2-oxo-N-p-tolyl-2H-chromene-3-carboxamide DMWXI6C Discovery agent N.A. Investigative [56]
2-oxo-N-phenyl-2H-chromene-3-carboxamide DMH8QWY Discovery agent N.A. Investigative [56]
2-p-tolyl-4,5-dihydro-1H-imidazole DM37S5C Discovery agent N.A. Investigative [49]
2-p-tolyl-4H-chromen-4-one DMFWA9Y Discovery agent N.A. Investigative [35]
2-p-tolyl-4H-chromene-4-thione DM2HKCM Discovery agent N.A. Investigative [35]
2-Phenethyl-4,5-dihydro-1H-imidazole DM4H6PC Discovery agent N.A. Investigative [53]
2-Phenoxymethyl-4,5-dihydro-1H-imidazole DM5E74G Discovery agent N.A. Investigative [53]
2-phenyl-9H-indeno[2,1-d]pyrimidine DMMHSYV Discovery agent N.A. Investigative [55]
2-Phenyl-cyclopropylamine hydrochloride DMUGH6J Discovery agent N.A. Investigative [57]
2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide DMZFKDW Discovery agent N.A. Investigative [37]
3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin DMN4Z27 Discovery agent N.A. Investigative [58]
3,4-Benzo-7-acetonyloxy-8-methoxycoumarin DM1MC06 Discovery agent N.A. Investigative [58]
3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide DMMZURL Discovery agent N.A. Investigative [59]
3-(2-Bromophenyl)-6-methylcoumarin DMDM0R6 Discovery agent N.A. Investigative [60]
3-(3-methoxyphenyl)-6-methyl-2H-chromen-2-one DMZQ2CJ Discovery agent N.A. Investigative [61]
3-(4-hydroxyphenyl)-6-methyl-2H-chromen-2-one DM3XOVL Discovery agent N.A. Investigative [61]
3-(4-methoxyphenyl)-6-methyl-2H-chromen-2-one DMXKJOC Discovery agent N.A. Investigative [61]
3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one DM2UPQG Discovery agent N.A. Investigative [55]
3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide DMIEZGD Discovery agent N.A. Investigative [59]
3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one DM830FW Discovery agent N.A. Investigative [55]
4,8-Dimethyl-7-(2'-oxocyclohexyloxy)coumarin DMQNXL1 Discovery agent N.A. Investigative [58]
4,9-Dihydro-3H-beta-carboline DM27HMT Discovery agent N.A. Investigative [46]
4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid DMWIALU Discovery agent N.A. Investigative [56]
4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one DMTB80W Discovery agent N.A. Investigative [37]
4-fluoroselegiline DMRC49E Dementia 6D80-6D86 Investigative [62]
4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN DMNMJDL Discovery agent N.A. Investigative [40]
4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one DM9K7CQ Discovery agent N.A. Investigative [58]
4-oxo-4H-chromene-3-carboxylic acid DM7GW4P Discovery agent N.A. Investigative [63]
4-phenyl-1,2,3,6-tetrahydropyridine DMV6WC4 Discovery agent N.A. Investigative [47]
5-Aminomethyl-3-pyrrol-1-yl-oxazolidin-2-one DMWDUVC Discovery agent N.A. Investigative [43]
5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMMI4H3 Discovery agent N.A. Investigative [14]
5-Bromo-4,9-dihydro-3H-beta-carboline DM2SEFR Discovery agent N.A. Investigative [14]
5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one DMT9FQN Discovery agent N.A. Investigative [43]
5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMNRSYA Discovery agent N.A. Investigative [14]
5-Methoxy-4,9-dihydro-3H-beta-carboline DMBOMZE Discovery agent N.A. Investigative [14]
5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE DMVX063 Discovery agent N.A. Investigative [64]
6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one DMU1CV4 Discovery agent N.A. Investigative [58]
6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMXQ8K1 Discovery agent N.A. Investigative [14]
6-Bromo-4,9-dihydro-3H-beta-carboline DM64KOZ Discovery agent N.A. Investigative [14]
6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMSA367 Discovery agent N.A. Investigative [46]
6-Methoxy-4,9-dihydro-3H-beta-carboline DM98FQO Discovery agent N.A. Investigative [46]
7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin DM762G3 Discovery agent N.A. Investigative [65]
7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin DMQCDT1 Discovery agent N.A. Investigative [58]
7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin DMQMTSX Discovery agent N.A. Investigative [58]
7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMVTH0Q Discovery agent N.A. Investigative [14]
7-Bromo-4,9-dihydro-3H-beta-carboline DMCWYT7 Discovery agent N.A. Investigative [14]
7-fluoro-2-(4-fluorophenyl)-4H-chromene-4-thione DM4HJZI Discovery agent N.A. Investigative [35]
7-fluoro-2-(4-methoxyphenyl)-4H-chromen-4-one DMUPXBJ Discovery agent N.A. Investigative [35]
7-fluoro-2-p-tolyl-4H-chromen-4-one DMFOU8G Discovery agent N.A. Investigative [35]
7-fluoro-2-p-tolyl-4H-chromene-4-thione DMJFXKA Discovery agent N.A. Investigative [35]
7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMQ1BE8 Discovery agent N.A. Investigative [53]
7-methoxy-2-p-tolyl-4H-chromen-4-one DME5WZQ Discovery agent N.A. Investigative [35]
7-methoxy-2-p-tolyl-4H-chromene-4-thione DM4WMGK Discovery agent N.A. Investigative [35]
7-Methoxy-9H-beta-carboline DMHKMU1 Discovery agent N.A. Investigative [14]
7-methyl-2-p-tolyl-4H-chromene-4-thione DMB9YA8 Discovery agent N.A. Investigative [35]
8-(3-Bromobenzyloxy)caffeine DM2RA4N Discovery agent N.A. Investigative [66]
8-(3-Chlorobenzyloxy)caffeine DM7HMNP Discovery agent N.A. Investigative [66]
8-(3-Fluorobenzyloxy)caffeine DME85GS Discovery agent N.A. Investigative [66]
8-(3-Methoxybenzyloxy)caffeine DMLY46X Discovery agent N.A. Investigative [66]
8-(3-Methylbenzyloxy)caffeine DMB9645 Discovery agent N.A. Investigative [66]
8-Benzyloxycaffeine DMJQ8AP Discovery agent N.A. Investigative [66]
8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMALRU4 Discovery agent N.A. Investigative [14]
8-Bromo-4,9-dihydro-3H-beta-carboline DM4V5RU Discovery agent N.A. Investigative [14]
8-Bromo-6-methyl-3-(4'-methoxyphenyl)coumarin DM51FL9 Discovery agent N.A. Investigative [60]
8-Bromo-6-methyl-3-phenylcoumarin DMD1LM8 Discovery agent N.A. Investigative [60]
8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMHE7J5 Discovery agent N.A. Investigative [14]
8-Methoxy-4,9-dihydro-3H-beta-carboline DM8MBSN Discovery agent N.A. Investigative [14]
8-[(3-Trifluoromethyl)benzyloxy]caffeine DMT3IOB Discovery agent N.A. Investigative [66]
9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline DMF7QS5 Discovery agent N.A. Investigative [14]
Benzyl-methyl-[1-(1H-pyrrol-2-yl)-vinyl]-amine DMQAEOL Discovery agent N.A. Investigative [67]
Beta-methoxyamphetamine DMA9CSG Discovery agent N.A. Investigative [68]
Butyl-methyl-prop-2-ynyl-amine hydrochloride DMJUTWG Discovery agent N.A. Investigative [69]
C-(1H-Indol-3-yl)-methylamine DMDLK9G Discovery agent N.A. Investigative [14]
CGS-19281A DMDB2KJ Discovery agent N.A. Investigative [46]
CHALCONE DM16QTM Discovery agent N.A. Investigative [70]
Cis-2-(4-chlorophenyl)-2-fluorocyclopropanamine DMVRF9H Discovery agent N.A. Investigative [71]
Cis-2-(para-fluorophenyl)cyclopropylamine DMPZ1LY Discovery agent N.A. Investigative [71]
Cis-2-Fluoro-2-(4-methoxyphenyl)cyclopropylamine DMNG9B2 Discovery agent N.A. Investigative [71]
Cis-2-fluoro-2-phenylcyclopropanamine DMFSPHE Discovery agent N.A. Investigative [71]
Cis-2-phenylcyclopropylamine DMKZ32J Discovery agent N.A. Investigative [71]
CORDOIN DMT5SED Discovery agent N.A. Investigative [70]
Deprenyl DMRFBD0 Discovery agent N.A. Investigative [72]
Farnesol DMV2X1B Discovery agent N.A. Investigative [40]
Flavanone DMNWIYM Discovery agent N.A. Investigative [35]
Flavin-Adenine Dinucleotide DM5S4GK Discovery agent N.A. Investigative [73]
Heptyl-methyl-prop-2-ynyl-amine hydrochloride DM1NUO5 Discovery agent N.A. Investigative [69]
HYDRAZINECARBOXAMIDE DMARWG5 Discovery agent N.A. Investigative [57]
IPRONIAZIDE DM42ENF Discovery agent N.A. Investigative [52]
Isopropyl-methyl-prop-2-ynyl-amine hydrochloride DM92F6Z Discovery agent N.A. Investigative [69]
JD-0100 DMLBX3Q Obesity 5B81 Investigative [8]
L-136662 DMWNJV0 Discovery agent N.A. Investigative [64]
Lauryl Dimethylamine-N-Oxide DM3W2OE Discovery agent N.A. Investigative [73]
LU-53439 DMGYBSC Discovery agent N.A. Investigative [74]
Methyl piperate DMW2R3M Discovery agent N.A. Investigative [21]
Methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine DM9Y4FL Discovery agent N.A. Investigative [45]
Methyl-pentyl-prop-2-ynyl-amine oxalic acid DMQ7THK Discovery agent N.A. Investigative [69]
MMDA DMUWVGP Discovery agent N.A. Investigative [73]
N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine DMCM51R Discovery agent N.A. Investigative [75]
N-(1H-Indol-2-ylmethyl)-N-phenylamine DMXD592 Discovery agent N.A. Investigative [75]
N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide DM7SUTQ Discovery agent N.A. Investigative [56]
N-(2-aminoethyl)-p-chlorobenzamide DMLSFQI Discovery agent N.A. Investigative [40]
N-(2-Methyl-1H-indol-5-yl)benzamide DMH42YF Discovery agent N.A. Investigative [59]
N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide DM3SF5M Discovery agent N.A. Investigative [59]
N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine DM1ADE5 Discovery agent N.A. Investigative [76]
N-(2-Phenylethyl)-1H-indole-2-carboxamide DMJCO7F Discovery agent N.A. Investigative [75]
N-(3-Phenylpropyl)-1H-indole-2-carboxamide DMKAX3Q Discovery agent N.A. Investigative [75]
N-(4-Ethylphenyl)-2-oxo-2H-chromene-3-carboxamide DMWTVJH Discovery agent N.A. Investigative [56]
N-(4-Phenylbutyl)-1H-indole-2-carboxamide DMTCMUG Discovery agent N.A. Investigative [75]
N-(benzyl),N-(pyrrol-2-ylmethyl)amine DM87YJW Discovery agent N.A. Investigative [76]
N-(propargyl),N-(pyrrol-2-ylmethyl)amine DMTJ5WL Discovery agent N.A. Investigative [76]
N-Benzyl,N-methyl-1H-indole-2-carboxamide DMHVRFM Discovery agent N.A. Investigative [75]
N-Benzyl-1H-indole-2-carboxamide DMA3YWU Discovery agent N.A. Investigative [75]
N-benzyl-2-oxo-2H-chromene-3-carboxamide DMJ29MN Discovery agent N.A. Investigative [56]
N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine DM0NJAL Discovery agent N.A. Investigative [75]
N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide DMRA548 Discovery agent N.A. Investigative [56]
N-isobutyl-2-oxo-2H-chromene-3-carboxamide DMO4E9U Discovery agent N.A. Investigative [56]
N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine DM83AEM Discovery agent N.A. Investigative [76]
N-methyl,N-(propargyl),N-(pyrrol-2-ylmethyl)amine DMZ24XT Discovery agent N.A. Investigative [76]
N-Methyl,N-phenyl-1H-indole-2-carboxamide DMM3B21 Discovery agent N.A. Investigative [75]
N-Methyl-N-phenyl-2-oxo-2H-chromene-3-carboxamide DMDB7ZM Discovery agent N.A. Investigative [56]
N-Methyl-N-Propargyl-1(R)-Aminoindan DMB9OGI Discovery agent N.A. Investigative [40]
N-Phenyl-1H-indole-2-carboxamide DM7V025 Discovery agent N.A. Investigative [75]
N-Propargyl-1(S)-Aminoindan DMHZCLV Discovery agent N.A. Investigative [40]
N2-[4-(benzyloxy)benzyl]glycinamide DMOZ1IY Discovery agent N.A. Investigative [42]
N2-{4-[(3-chlorobenzyl)oxy]benzyl}glycinamide DMHJ2IP Discovery agent N.A. Investigative [42]
N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide DMEWP9L Discovery agent N.A. Investigative [42]
N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide DMLPJGX Discovery agent N.A. Investigative [42]
N2-{4-[(4-nitrobenzyl)oxy]benzyl}glycinamide DMAVB0G Discovery agent N.A. Investigative [42]
NSC-50187 DMTQP3V Discovery agent N.A. Investigative [35]
NSC-93405 DM3BZ7S Discovery agent N.A. Investigative [35]
NW-1772 DMRYBK6 Neurodegenerative disorder 8A20-8A23 Investigative [8]
Phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate DMHDWTS Discovery agent N.A. Investigative [49]
PNU-22394 DMHTPSF Discovery agent N.A. Investigative [14]
RS-1636 DMKQT1Y Discovery agent N.A. Investigative [10]
SKL-PD DM4X2GH Central nervous system disease 8A04-8D87 Investigative [8]
TOLOXATONE DMHV5NK Discovery agent N.A. Investigative [43]
TRACIZOLINE DM18CV3 Discovery agent N.A. Investigative [53]
Trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine DMH1S57 Discovery agent N.A. Investigative [71]
Trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine DMO01T8 Discovery agent N.A. Investigative [71]
Trans-2-fluoro-2-p-tolylcyclopropanamine DM392QT Discovery agent N.A. Investigative [71]
Trans-2-fluoro-2-phenylcyclopropylamin DMVGAFR Discovery agent N.A. Investigative [71]
TRYPTOLINE DMV19K7 Discovery agent N.A. Investigative [53]
VAR-10200 DMD7M9L Neurodegenerative disorder 8A20-8A23 Investigative [8]
VAR-10300 DMFKTPO Neurodegenerative disorder 8A20-8A23 Investigative [8]
[(1e)-4-Phenylbut-1-Enyl]Benzene DMG1ATX Discovery agent N.A. Investigative [40]
⏷ Show the Full List of 237 Investigative Drug(s)

References

1 Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
4 Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
5 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
6 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
7 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
9 Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
10 Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
11 Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
12 Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46.
13 Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
14 Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
15 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
18 Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA
19 Sembragiline Alzheimer's Disease (Phase 2). Evotech AG, Roche.
20 Company report (Neurim Pharmaceuticals)
21 Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
22 Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
23 Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
24 MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
25 LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
26 The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62(8):727-37.
27 A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
28 mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
29 Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B. J Med Chem. 2008 Dec 25;51(24):8019-26.
30 Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther. 2009 May;85(5):506-12.
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034020)
32 [(11)C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: preclinical characterisation in nonhuman primate. Synapse. 2010 Jan;64(1):61-9.
33 Milacemide, the selective substrate and enzyme-activated specific inhibitor of monoamine oxidase B, increases dopamine but not serotonin in caudate nucleus of rhesus monkey. Neurochem Int. 1990;17(2):325-9.
34 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95.
35 A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9.
36 Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60.
37 Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706.
38 Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13.
39 Synthesis and in vitro evaluation of pteridine analogues as monoamine oxidase B and nitric oxide synthase inhibitors. Bioorg Med Chem. 2009 Nov 1;17(21):7523-30.
40 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
41 Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4438-46.
42 Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16.
43 3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3.
44 Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206.
45 Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site. J Med Chem. 1988 Aug;31(8):1558-66.
46 Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
47 Further explorations of unnatural alkaloids. J Nat Prod. 1985 Nov-Dec;48(6):878-93.
48 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
49 Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9.
50 Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70.
51 3-[5-(4,5-dihydro-1H-imidazol-2-yl)-furan-2-yl]phenylamine (Amifuraline), a promising reversible and selective peripheral MAO-A inhibitor. J Med Chem. 2006 Sep 7;49(18):5578-86.
52 Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
53 Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
54 New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A ... Bioorg Med Chem. 2009 Jan 15;17(2):675-89.
55 Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71.
56 Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
57 Fluorinated phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of absolute configuration on inhibition of microbial tyramine oxi... J Med Chem. 2004 Nov 18;47(24):5860-71.
58 Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51.
59 Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66.
60 New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5157-60.
61 Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5053-5.
62 Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch Int Pharmacodyn Ther. 1994 Jul-Aug;328(1):1-15.
63 Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B. Bioorg Med Chem Lett. 2010 May 1;20(9):2709-12.
64 Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5295-8.
65 Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007 Nov 15;50(23):5848-52.
66 Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28.
67 Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B. J Med Chem. 2003 Mar 13;46(6):917-20.
68 Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
69 Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem. 1992 Oct 2;35(20):3705-13.
70 Chalcones: a valid scaffold for monoamine oxidases inhibitors. J Med Chem. 2009 May 14;52(9):2818-24.
71 Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66.
72 The effect of deprenyl washout in patients with long-standing Parkinson's disease. J Neural Transm. 2002 May;109(5-6):797-803.
73 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
74 Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92.
75 Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40.
76 New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31.
77 Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32.